Incretin Atlas › Molecules › ASC30
ASC30
GLP-1 (small molecule) · oral / s.c. · Ascletis
Summary
- Also known as
- Ascletis (oral small molecule and injectable)
- Mechanism
- GLP-1 (small molecule)
- Route
- oral / s.c.
- Company
- Ascletis
- Highest development stage
- phase 3
- Status (as of data cut)
- Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026) verify
- Next milestone
- Phase 3
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | Oral phase 2 positive (13 weeks); phase 3 AURORA started Aug 2026 | |
| T2D | 2 phase 3 ongoing | U.S. phase 2 topline (company release, October 2026): HbA1c 1.6–1.7 points and weight 3.8–4.4 % below placebo at 12–13 weeks; phase 3 registered on ClinicalTrials.gov | Ascletis release, 28 Oct 2026 |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Registered trials (2)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| AURORA-2 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-08 → 2028-07 | 1560 | recruiting | NCT07743450 |
| AURORA-1 A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Obesity | Phase 3 | recruiting | 2026-08 → 2028-07 | 3003 | recruiting | NCT07743463 |
Primary sources
No source recorded.
How to cite this page
Medical Adviser's Group. Incretin Atlas: ASC30. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/asc30/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.